or Try an Advanced Search...

    Stage Biopharmaceutical Stocks List

    Symbol Grade Name % Change
    GTBP D GT Biopharma, Inc. 150.00
    INKT D MiNK Therapeutics, Inc. 0.00
    PULM D Pulmatrix, Inc. 3.14
    ONCY D Oncolytics Biotech Inc. 0.90
    OCUL D Ocular Therapeutix, Inc. 1.94
    ASND D Ascendis Pharma A/S -0.04
    CLRB D Cellectar Biosciences, Inc. -4.24
    SGMO D Sangamo BioSciences, Inc. -5.39
    AVTE D Aerovate Therapeutics, Inc. -1.94
    ACXP F Acurx Pharmaceuticals, Inc. -0.89
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - General
    Related Stock Lists: Biotechnology Life Sciences Cancer Biopharmaceutical Hypertension Medicine Blastoma Clinical Medicine Glioblastoma Pulmonary Arterial Hypertension Solid Tumors Stem Cell Advanced Solid Tumors Allergic Conjunctivitis Allergology Antibiotics Antineoplastic Drugs Bacterial Infections Biology Breakthrough Therapy

    Related ETFs - A few ETFs which own one or more of the above listed Stage Biopharmaceutical stocks.

    Symbol Grade Name Weight
    LABD F Direxion Daily S&P Biotech Bear 3X Shares 0.77
    SBIO C ALPS Medical Breakthroughs ETF 0.68
    BIS F ProShares UltraShort Nasdaq Biotechnology 0.35
    DWAS B PowerShares DWA SmallCap Technical Leaders Portfolio 0.27
    BTEC C Principal Healthcare Innovators Index ETF 0.1
    View all Stage Biopharmaceutical ETFs...
    Compare ETFs
    Compare SBIO to BIS Compare SBIO to BTEC Compare SBIO to DWAS

        Stage Biopharmaceutical Stocks Recent News

        Date Stock Title
        May 20 CLRB Cellectar Biosciences: Still Working On That Hit (Maintain Buy)
        May 17 PULM Pulmatrix files for $95M mixed shelf
        May 16 ONCY Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
        May 16 ACXP Acurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...
        May 16 ACXP Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
        May 15 ASND FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
        May 15 ACXP Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript
        May 15 ASND FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
        May 15 PULM Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
        May 15 ACXP Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
        May 15 ACXP Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
        May 15 ONCY Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
        May 15 ACXP Acurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04
        May 15 CLRB Q1 2024 Cellectar Biosciences Inc Earnings Call
        May 15 CLRB Cellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
        May 14 ASND US Equity Markets Close Higher Tuesday as Producer Prices Rise
        May 14 ASND Ascendis Pharma says FDA has delayed TransCon PTH review
        May 14 ASND UPDATE 1-FDA extends review of Ascendis Pharma's hormone disorder therapy
        May 14 ASND Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
        May 14 CLRB Cellectar Biosciences, Inc. 2024 Q1 - Results - Earnings Call Presentation
        Related Industries: Biotechnology Drug Manufacturers - General
        Related Stock Lists: Medicine Biotechnology Chronic Obstructive Pulmonary Disease Clinical Medicine Cystic Fibrosis Life Sciences Organ Systems Pulmonary Fibrosis Acute And Chronic Pain Acute Myeloid Leukemia Acute Pain Age Related Diseases Alcohol Alopecia Areata Analgesics Angiogenesis Angiology Antidepressants Antiviral Therapies Asthma
        Stage Biopharmaceutical

        Browse All Tags